India, Nov. 17 -- Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission (EC) has approved an alternative dosing schedule for Libtayo (cemiplimab) across all six approved skin, lung and cervical cancer indications in the European Union.

Under the new regimen, patients who complete the initial 12 weeks of treatment with Libtayo 350 mg every three weeks may receive a higher 700 mg dose every six weeks. Both doses are administered intravenously over 30 minutes.

The approval also allows patients who tolerate their first 30-minute infusion of Libtayo 350 mg to receive subsequent infusions of the same dose over 15 to 30 minutes, potentially reducing infusion time by half.

The approval is supported by clinical safety and ...